{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-019083","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.649848+00:00","generated_at":"2026-06-20T06:32:42.951850+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst completes $160M acquisition of U.S. rights to FYCOMPA from Eisai, expects accretion in 2023","bullets":["Paid $160M upfront all-cash to Eisai; potential milestone/royalty payments under certain conditions.","FYCOMPA net revenue for FY ending March 31, 2023 expected ~$136M; gross margin similar to FIRDAPSE.","Eisai will supply FYCOMPA for 7 years and provide transition services for up to 180 days post-closing.","Acquisition expected to be accretive to EBITDA and EPS in 2023; FIRDAPSE revenue guidance unchanged at $205-210M.","Overlaps ~45% with FIRDAPSE physician call points; strengthens neuroscience portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-019083","json":"https://secwatch.observer/filing/0001193125-23-019083.json","markdown":"https://secwatch.observer/filing/0001193125-23-019083.md","text":"https://secwatch.observer/filing/0001193125-23-019083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/0001193125-23-019083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/d103110d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:32:42.951850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"780438f2ee3e5a28ab68ac57ea7a4ed2d5b67693","claim":"CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Eisai Co., Ltd. for $160 million (closed 2023-01-24).","evidence_excerpt":"Asset Purchase Agreement (the “ Purchase Agreement ”) between the Company and Eisai. Under the terms of the Purchase Agreement, the Company paid an upfront payment to Eisai of $160 million. Also at the closing of the asset purchase, the parties entered into two related agreements: (i) a short term Transition Services Agreement (the “ Transition Services Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/0001193125-23-019083-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Eisai Co., Ltd."},{"label":"Consideration","value":"$160 million"},{"label":"Closing","value":"2023-01-24"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}